

May 03, 2021

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sir,

Sub: Glenmark launches Ryaltris®-AZ at an affordable price in India

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH
VINAYAK KUBER

Digitally signed by HARISH
VINAYAK KUBER
Date: 2021.05.03 09:49:12
+05'30'

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Press release

For immediate distribution

Glenmark launches Ryaltris®-AZ at an affordable price in India

- *Glenmark becomes the first company in the world to launch Ryaltris®-AZ as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg.*
- *Ryaltris®-AZ Nasal Spray relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes*
- *Glenmark launches Ryaltris®-AZ at competitive pricing of just Rs. 175/- per pack of 75 metered doses (MD), around 52% less as compared to the average price of the top 10 brands of the similar drugs category, in the market.*

Mumbai, India; May 3, 2021: Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, announced the launch of Ryaltris®-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost effective treatment option in the country.

Glenmark is the first company in the world to launch Ryaltris®-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg.

According to a study, around 20-30 % of the Indian population suffers from allergic rhinitis¹. Moreover, in India, patients have to bear the drug cost on their own and so the price of the drug becomes a major factor that impacts treatment adherence. While the average cost of therapy of top 10 existing brands of the similar drug category is Rs. 365, Glenmark's Ryaltris®-AZ nasal spray has been launched at a breakthrough price of Rs. 175/- per pack of 75 metered doses (MD). This cost is around 52% less as compared to the average price of the top 10 brands of the similar drug category in the market.

Ryaltris®-AZ nasal spray, developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age. It relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.

Alok Malik, Group Vice President & Business Head, India Formulations said "Glenmark has been a pioneer in providing access to the latest treatment options for respiratory disease patients in India. We are glad to introduce our brand Ryaltris®-AZ, which is clinically studied and cutting-edge, at an affordable cost for patients in the country. Respiratory segment is a key area of focus for Glenmark and the launch of this product will enable us to improve access to allergic rhinitis treatment by providing an effective, convenient, world-class and affordable treatment option to patients in India," .

Allergic rhinitis is a chronic upper respiratory disease estimated to affect around 10 to 40% of the population worldwideⁱⁱ. Indeed, allergic rhinitis contributes to missed or unproductive time at work, sleep problems and decreased involvement in outdoor activities. Being a topical therapy Ryaltris®-AZ offers many advantages over oral therapies, such as delivering greater concentrations of drug to the receptor sites at the source of the allergic inflammation and reduced risk of systemic side effectsⁱⁱⁱ.

Optimized and quick symptom relief in allergic rhinitis is achieved with combination therapy of an intranasal corticosteroid (INCS) and intranasal antihistamine (INAH) nasal spray, as compared to other treatments. Renewed ARIA (Allergic Rhinitis & its impact on Asthma) guidelines recommend Intranasal Corticosteroid & Intranasal Antihistamine as a 1st line of treatment in moderate to severe Allergic Rhinitis. With technological advantage & competitive pricing with Ryaltris®-AZ, Glenmark aims to pass on this benefit to Indian patients who suffer from Moderate to Severe Allergic Rhinitis.

—End—

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). The company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world's most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index. For more information, visit www.glenmarkpharma.com

For more information:

Glenmark Media Contacts

Udaykumar Murthy

Senior Manager, Corporate Communications

+91 9960377617

corpcomm@glenmarkpharma.com

References:

-
- i Varshney J, Varshney H. Allergic Rhinitis: an Overview. Indian J Otolaryngol Head Neck Surg. 2015 Jun;67(2):143-9. doi: 10.1007/s12070-015-0828-5. Epub 2015 Jan 31. PMID: 26075169; PMCID: PMC4460099.
- ii Watts Annabelle M., Cripps Allan W., West Nicholas P., Cox Amanda J. Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents <https://www.frontiersin.org/article/10.3389/fphar.2019.00294>
- iii Watts AM, Cripps AW, West NP, Cox AJ. Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents. Front Pharmacol. 2019;10:294. Published 2019 Mar 29. doi:10.3389/fphar.2019.00294